News Releases

2013

XXX
Dec.24.2013
ONO Files for Regulatory Approval of "Nivolumab (ONO-4538/BMS-936558)" for Treatment of Malignant Melanoma(24.1KB)
XXX
Dec.16.2013
FDA Advisory Committee Recommends the Investigational SGLT2 Inhibitor Dapagliflozin for the Treatment of Type 2 Diabetes in Adults(423KB)
XXX
Dec.13.2013
Ono Establishes a Local Subsidiary in South Korea(63.3KB)
XXX
Dec.09.2013
Clinical Trial Application submitted for Phase I study of ONO-7268MX2, peptide-cocktail vaccine for hepatocellular carcinoma(86.9KB)
XXX
Dec.03.2013
AstraZeneca and Ono Enter Co-promotion Agreement in Japan for Dapagliflozin(94.3KB)
XXX
Nov.22.2013
Approval for Additional Indication of Onoact® 50 for injection, Short-Acting Selective β1 Blocker in Japan(117KB)
XXX
Nov.14.2013
Results of Phase II/III Study of ONO-2745/CNS 7056, a Short-acting General Anesthetic(89.8KB)
XXX
Nov.05.2013
Announcement on Financial Results for FY2013 2Q
XXX
Oct.28.2013
Fully Human Anti-PD-1 Antibody "Nivolumab (ONO-4538/BMS-936558)" Updated Results from a Phase 1 Study in Patients with NSCLC Presented at 15th World Conference on Lung Cancer(84.1KB)
XXX
Oct.22.2013
Ono Enters into License Agreement with Valeant(88.5KB)
XXX
Oct.09.2013
Ono Establishes a Local Subsidiary in South Korea(41.8KB)
XXX
Oct.01.2013
Fully Human Anti-PD-1 Antibody "Nivolumab (ONO-4538/BMS-936558)" Result from Phase II Study in Patients with Melanoma Presented at European Cancer Congress 2013(64.4KB)
XXX
Sep.27.2013
Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced(57.6KB)
XXX
Sep.03.2013
Announcement on Annual Report 2013
XXX
Aug.27.2013
Rheumatoid Arthritis Drug ORENCIA® SC 125mg Syringe 1mL Launched in Japan(135KB)
XXX
Aug.13.2013
Ono Pharmaceutical and MSD applied for partial change in indications of "Sitagliptin", to add "type 2 diabetes"(45.9KB)
XXX
Aug.06.2013
Application Submission for Approval for the Stability-Improved Formulation of Limaprost,an Oral Prostaglandin E1 Analogue in Japan(28.0KB)
XXX
Aug.02.2013
Announcement on Financial Results for FY2013 1Q
XXX
Aug.02.2013
"Glactiv® tablets"for the oral treatment of type 2 diabetes Contraindication was removed and replaced by careful administration in patients with severe renal insufficiency(109KB)
XXX
July.05.2013
Subcutaneous (SC) formulation of ORENCIA® (abatacept) Results of Year Two Data from AMPLE Study in Patients with Moderate to Severe Rheumatoid Arthritis Presented at the European League Against Rheumatism (EULAR) Annual Congress(296KB)
XXX
Jun.28.2013
Rheumatoid Arthritis Drug ORENCIA® SC 125mg Syringe 1mL Approved for Production and Distribution(90.8KB)
XXX
Jun.04.2013
Bristol-Myers and Ono Pharmaceutical to Announce Lifting of Approval Conditions (Completion of PMS: "All-Case Surveillance") and Start of Co-Promotion(71.3KB)
XXX
Jun.03.2013
Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Patients with Melanoma Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)(217KB)
XXX
May.16.2013
Detailed Results of Phase III Trial of L-BLP25 in Patients with Non-Small Cell Lung Cancer (START) to be Presented at ASCO(67.2KB)
XXX
May.13.2013
Voluntary adoption of International Financial Reporting Standards (IFRS)(134KB)
XXX
May.13.2013
Partial Amendment of Articles of Incorporation(16.9KB)
XXX
May.13.2013
Announcement on Financial Results for FY2012
XXX
May.09.2013
Announcement on Candidates of Members of the Board of Directors,Corporate Auditors and Corporate Officers(13.9KB)
XXX
May.08.2013
Ono and Dainippon Sumitomo reach agreement on expanding business relating to Limaprost into China(15.7KB)
XXX
Apr.18.2013
Ono Enters into License Agreement with Bial(9.8KB)
XXX
Feb.20.2013
Additional Indication Application filed for Onoact® 50 for injection,Short-Acting Selective β1 Blocker in Japan(80.1KB)
XXX
Feb.04.2013
Announcement on Financial Results for FY2012 3Q
XXX
Jan.25.2013
Discontinuation of Development for the Additional Indication of Carpal-Tunnel Syndrome, for Limaprost, an Oral Prostaglandin E1 Analogue(13.3KB)